Jean-bernard Durand MD, FACC, FACP, FCCP, FHFSA, FAHA

Dr. Durand completed training in clinical and basic science. While completing his residency in internal medicine, at Loyola University School of Medicine in Chicago. He completed an American Heart Association/Bugher Foundation Fellowship in Molecular Biology investigating Hypertrophic Cardiomyopathy and Dilated Cardiomyopathy. He was awarded a Robert Woods Johnson Fellowship at Baylor College of Medicine in Molecular Genetics. This body of work lead to the Localization of a gene to Chromosome 1q32 and the Identification of the gene as Troponin, one of the first genes for Familial dilated Cardiomyopathy.

After completion of his clinical fellowship at Baylor College of Medicine, He also completed a clinical fellowship in Immunology/Advanced Heart Failure/ Circulatory Support and Cardiac Transplantation. He served as Assistant Medical Director of the Heart Transplant Service at Baylor College of Medicine.

He was recruited to MD Anderson Cancer Center to establish a cardiomyopathy program and a fully integrated interventional cardiology program. He was the first to establish a cardiomyopathy service within a cancer hospital and was able to establish standards for cardioprotection prior to Anthracycline-based therapies and investigate novel mechanisms which lead to recovery of cardiac function in chemotherapy induced cardiomyopathy from Anthracyclines, Tyrosine Kinase Inhibitors, and radiation-induced cardiomyopathy.

Dr. Durand developed the largest DNA/Tissue bank of Chemotherapy-induced Cardiomyopathy to detect polymorphisms to predict the risk of development of heart failure. He has developed the first cardiac device clinic at MD Anderson utilizing mobile device monitoring of patients with arrhythmias and heart failure. He has over 100 publications in peer-reviewed journals.

He serves as an IRB Co-chair and is a national and international speaker for cardiology, he was recently appointed to the American Heart Association New Cardioncology Council and serves as Co-PI on several clinical trials for Stem Cell Therapy for Anthracycline- induced Cardiomyopathy.